Factors affecting survival in breast cancer patients referred to the Darol Aitam-e Mahdieh center

Journal of Zanjan University of Medical Sciences and Health Services

Volumn 22, Issue 93, 2014, Pages 105-115

  Fardmal, J ^a   Mafi, M ^b   Sadighi Pashaki, A ^c   Karami, M ^a   Roshanaei, G H ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Radiology Oncology Center   (Iran)

Author keywords

Breast cancer; Survival analysis; Time dependent Cox model

Indexed keywords

PROGESTERONE RECEPTOR;

AGE; ARTICLE; BREAST CANCER; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

EID: 84940335508     PISSN: 16069366     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cancer office of center for disease control and prevention. Iranian annual of national cancer registration report 2005-2006. Tehran: Ministry of health and medical education of I.R. Iran, 2007. (Persian) Available from: http://www. emro.who. int/ncd/pdf/cancer_registry_iran.
2. Cox J, Ang K. Radiation oncology: rationale, technique, results.9ed. Philadelphia: Mosby Inc. 2009.
3. DeVita V, Lawrence T, Rosenberg S. Cancer: principles & practice of oncology.8ed. Philadelphia: Lippincott Williams Wilkins; 2008.
4. Ministry of health and medical education. Report of national cancer registration. (persian). 2008.
5. Cancer registry report in Iran. Center of management of noncontiguous diseases. Ministry of health and medical education 2004.
6. Bakhtyari A, Hajyan K. Five year disease-free survival rate in breast cancer patients in Rajaii hospital. (Persian). J Sch Public Health Inst Public Health Res. 2007; 5: 53-60.
7. Tewsend M, Neauchamp R, Daniel S, Matto X Kenneth L. Sabiston text book of surgery. 17ed. Amsterdam: Elsevier; 2004.
8. Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roche H. Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol. 2005; 55: 167-75.
9. Faradmal J, Kazemnejad A, Khodabakhshi R, Gohari M, Hajizadeh E. Comparison of chemotherapy regimes using an extended loglogistic model in women with three adjuvant operable breast cancer. Asian Pac J Cancer Prev. 2010; 11: 353-8.
10. Harbeck N. Adjuvant chemotherapy in primary breast cancer. Onkologie. 2003; 26: 17-20.
11. Cowper D, Kubal J, Maynard C, Hynes D. A primer and comparative review of major S mortality databases. Ann Epidemiol. 2002; 462: 8-12.
12. Lamont BE, Herndon EJ, Weeks CJ, Henderson I, Craig CE, Schilsky LRea. Measuring disease-free survival and cancer relapse using medicare claims from calgb breast cancer trial participants. JNCI. 2006; 98: 1335-8.
13. Moradi Marjane M, Homaee Shandiz F, Shamsian A, et al. Association between Her2/neu, P53, ER and PR genes with survival rate in Iranian wemon with breast cancer (persian). Iran J Breast Dis. 1378; 1: 7-17.
14. Salehi M, Gohari M, Vahabi N, Zayeri F, Yahyazadeh S, Kafashian M. Comparison of artificial neural network and cox regression models in survival prediction of breast cancer patients.(persian). J Ilam Univ Med Sci. 2013; 21: 120-8.
15. Yaghmaei S, Bani Hashemi G, Gorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran. (1991-2002). (persian). J Semnan Univ Med Sci. 2007; 2: 6-11
16. Moetamed N, Negin H, Taleei A. Evaluation of risk factor on women of older than 35year with breast cancer in Shiraz-2001. J Zanjan Univ Med Sci. 2004; 12: 25-33.
17. Mousavi Naeni S, Mofid B, Mohebi H, Mehmanavaz M, Khoshini S. Comparison of local recurence, metastasis and survival rates between the two surgical methods in the treatment of stsge I and II breast cancer. Kowsar J. 2009; 14: 89-94.
18. Gohari M, Mahmoudi M, Kazem M, Pasha E, Khodabakhshi R. Recurrence in breast cancer analysis with frailty model. Saudi Med J. 2006; 27: 117-93.
19. Vahdaninia M, Montazeri A. Breast cancer in Iran: a survival analysis. Asian Pac J Cancer Prev. 2004; 5: 223-25.
20. Mousavi S, Mohagheghi M, Mousavi Jerrahi A, Nahvijou A, Seddighi Z. Outcome of breast cancer in Iran: a study of Tehran center registry data. Asian Pac J Cancer Prev. 2008; 9: 275-78.
21. Sajadi A, Gregory H, Bajdik C, et al. Comparison of breast cancer survival in two populations: Ardabil, Iran and British Columbia, Canada. BMC Cancer. 2009; 381: 86-9.
22. Akbari M, Khayamzadeh M, Khoshnevis S, Nafisi N. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. Iran J Cancer Prev. 2008; 1: 53-6.
23. Heydari S, Mehrabani D, Tabei S, Azarpira N, Vakili M. Survival of breast cancer in southern Iran. Iran J Cancer Prev. 2009; 51: 1-4.
24. Khodabakhshi R, Gohari M, Moghadamifard Z, Foadzi H, Vahabi N. Disease-free survival of breast cancer patients and identification of related factors. Razi J Med Sci. 2011; 18: 27.
25. Ivanauskienë R, Gedminaitë J, Juozaitytë E, Vanagas G,. imoliûnienë R, Padaiga. Survival of women with breast cancer in kaunas region, Lithuania. Medicina (Kaunas). 2011; 48: 272-6.
26. Venkatesan P, Raman T, Ponnuraja C. Survival analysis of women with breast cancer under adjuvant therapy in South India. Asian Pacific J Cancer Prev. 2011; 1533: 5-12.
27. Pajares B, Pollán M, Martín M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res. 2013; 1: 14-18.
28. Del Turco M, Ponti A, Bick U, et al. Quality indicators in breast cancer care. Eur J Cancer. 2010; 23: 46-56.
29. Martos MC, Saurina C, Feja C, et al. Accurately estimating breast cancer survival in Spain: cross-matching local cancer registries with the national death index. Pan Am J Public Health. 2009; 26: 51-4.
30. Baitchev G, Gortchev G, Velkova A, Deliisky T. Predictors of recurrence in stage I invasive breast carcinoma. Radiol Oncol. 2001; 35: 133-37.
31. Wishart GC, Azzato EM, Rashbass J, et al. A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010; 1: 10-12.
32. Putter H, van der Hage J, de Bock GH, Elgalta R van de Velde CJH. Estimation and prediction in a multi-state model for breast cancer. J Biometrical. 2006; 48: 366-80.
33. Beck P, Diane K, Downey W, Butler J. Statin use and the risk of breast cancer. JCE. 2003; 280: 56-85.
34. Habibi G, Leung S, Jennifer H, et al. Redefining prognostic factors for breast cancer: YB-1is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2across all tumor subtypes, Breast Cancer Res. 2008; 10: 32-41.
35. Yoshida M, Shimizu C, Fukutomi T, et al. Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis. Jpn J Clin Oncol. 2011; 41: 180-89.
36. Heitz F, Rochon J, Harter P, et al. Cerebral metastases in metastatic breast cancer: diseasespecific risk factors and survival. Ann Ancol. 2011; 22: 1571-81.
37. Louis P, Pertschuk D, Joseph G, et al. Immuonocytochermical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, diseasefree survival and clinical endocrine response. Cancer. 2006; 62: 342-9.
38. Horita K, Yamaguchi A, Hirose K, et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem. 2001; 45: 73-84.
39. Koizumi M, Yoshimoto M, Kasumi F, Iwase T. An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer. 2010; 381: 85-10.